These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31129911)

  • 21. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
    Park SD; Baek YS; Woo SI; Kim SH; Shin SH; Kim DH; Kwan J; Park KS
    Trials; 2014 May; 15():151. PubMed ID: 24885437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y
    Audia JP; Yang XM; Crockett ES; Housley N; Haq EU; O'Donnell K; Cohen MV; Downey JM; Alvarez DF
    Basic Res Cardiol; 2018 Jul; 113(5):32. PubMed ID: 29992382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
    Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
    Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):121-130. PubMed ID: 31645108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
    Alexopoulos D; Pappas C; Sfantou D; Xanthopoulou I; Didagelos M; Kikas P; Ziakas A; Tziakas D; Karvounis H; Iliodromitis E
    J Am Coll Cardiol; 2018 Oct; 72(14):1750-1751. PubMed ID: 30261967
    [No Abstract]   [Full Text] [Related]  

  • 28. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Wang X; Li X; Wu H; Li R; Liu H; Wang L; Bai S; Zhang L; Chen T; Liu J; Li Q; Du R
    Coron Artery Dis; 2019 Aug; 30(5):317-322. PubMed ID: 30614823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Hematologic Parameters on Microvascular Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.
    Karahan Z; Uçaman B; Uluğ AV; Aydınalp Ö; Uğurlu M; Çevik K; Kaya İ; Öztürk Ö
    Angiology; 2016 Feb; 67(2):151-6. PubMed ID: 26007233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
    Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
    Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cangrelor: A Review in Percutaneous Coronary Intervention.
    Keating GM
    Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.
    Silverio A; Bellino M; Scudiero F; Attisano T; Baldi C; Catalano A; Centore M; Cesaro A; Di Maio M; Esposito L; Granata G; Maiellaro F; Muraca I; Musumeci G; Parodi G; Personeni D; Valenti R; Vecchione C; Calabrò P; Galasso G
    J Thromb Thrombolysis; 2024 Jun; 57(5):757-766. PubMed ID: 38615155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
    Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
    Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.